



## Working Conference

# Classification and Management of Mast Cell Neoplasms in Dogs and Humans: A Comparative Oncology Approach

Vienna, May 17, 2019

**Friday, May 17**

**Aula of the University of Vienna, Old General Hospital of Vienna**

8:00 Welcome Coffee

8:15 Welcome Notes

Petra Winter, Rector of the University of Veterinary Medicine Vienna

8:20 Introduction and Background

Michael Willmann and Peter Valent

8:30-10:00 Session I: Mast Cells in Health and Disease

Chair: M. Dacasto and D.M. Vail

8:30 Biology and Roles of Mast Cells – The Beauty & The Beast

Stephen J. Galli (Stanford, CA, USA)

9:00 Mast Cell Activation: Basic Concepts and Clinical Implications

Erika Jensen-Jarolim (Vienna, Austria)

9:20 Mast Cells in Human Neoplastic Diseases

Peter Valent (Vienna, Austria)

9:40 Mast Cells in Canine Neoplastic Diseases

Michael Willmann (Vienna, Austria)

10:00 Coffee Break

10:40-12:20 Session II: Molecular Markers and Targets in Mast Cell Neoplasms

Chairs: L. Marconato and M. Kiupel

10:40 *KIT* Mutation Analysis in Human Mast Cell Neoplasms

Michel Arock (Paris, France)

- 11:00 *KIT* Mutation Analysis for Diagnosis and Prognostication in Canine MCT  
TBD
- 11:20 *SRSF2, ASXL1, RUNX1, JAK2* and other 'Non-*KIT* Mutations':  
Diagnostic and Prognostic Value in Systemic Mastocytosis  
Mohamad Jawhar (Mannheim, Germany)
- 11:40 Mutational *TET2, IDH1, IDH2, SRSF2, SF3B1* and *RAS*:  
Are they Detectable and Relevant in Canine MCT?  
Mauro Dacasto (Padova, Italy)
- 12:00 CDK6 as Key Regulator of Leukemic Stem Cells  
Veronika Sexl (Vienna, Austria)
- 12:20 Lunch Buffet
- 13:30-14:40 Session III: Pathology, Grading and Staging of Mast Cell Neoplasms  
Chair: H.-P. Horny and S.J. Galli
- 13:30 Histopathology and Immunohistochemistry in Mastocytosis: Status 2019  
Hans-Peter Horny (Munich, Germany)
- 14:00 Canine MCT: A Combined Clinical and Pathologic Approach  
to Diagnosis and Prognosis  
Matti Kiupel (East Lansing, Michigan, USA)
- 14:20 The Role of the Lymph Node in Canine Mast Cell Tumors  
Laura Marconato (Bologna, Italy)
- 14:40 Coffee Break
- 15:00-17:00 Session IV: Basic and Translational Research in Human and Canine  
Mast Cell Disorders  
Chair: E. Hadzijusufovic and M. Müller
- 15:00 Delineation of Markers and Targets in Neoplastic Stem Cells in ASM and MCL  
Gregor Eisenwort (Vienna, Austria)
- 15:20 Value of Diamine Oxidase as Novel Marker of Mast Cell Activation  
Thomas Böhm & Bernd Jilma (Vienna, Austria)
- 15:40 STAT5 as Marker and Therapeutic Target in Hematopoietic Neoplasms  
Richard Moriggl (Vienna, Austria)
- 16:00 Establishment of iPSC from Patients with Mast Cell Neoplasms  
Mathias Schneeweiß (Vienna, Austria)
- 16:20 Role of TRKA Receptor in the Etiology of Mastocytosis in Mice and in the  
Development of Resistance against *KIT*-Targeted Therapy  
Zhixiong Li (Hannover, Germany)

16:40 Genetic Mouse Models for Evaluating Oncogenesis in Hematopoietic Neoplasms  
Mathias Müller (Vienna, Austria)

17:00 Coffee Break

17:30-19:00 Session V: Markers in Human and Canine Mast Cell Neoplasms  
Chair: P. Valent and M. Arock

17:30 The Serum Tryptase Test: A Robust Biomarker in Human Mastocytosis  
Wolfgang R. Sperr (Vienna, Austria)

17:50 Serum Tryptase Measurements in Canine Mastocytoma  
David M. Vail (Madison, WI, USA)

18:10 Diagnostic and Prognostic Value of Aberrant CD2, CD25 and CD30  
in Human Mast Cell Neoplasms  
Karl Sotlar (Salzburg, Austria)

18:30 Effects of Ibrutinib on Growth and Function of Neoplastic Canine Mast Cells  
Susanne Gamperl (Vienna, Austria)

18:50 Summary  
Peter Valent